Unraveling complexity. Harnessing insights.
Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways.
We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a dual PI3K – mTOR inhibitor.
We are a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.
Our third-generation cellular analysis platform unravels complex oncogenic activity molecular tests can’t detect.
See our approach
Our discoveries create new potential applications for targeted therapies.
View our pipeline
Our comparative analyses of different drugs use live patient tumor cells, revealing opportunities to develop first-in-class drugs.
Learn about Gedatolisib